Exact Mass: 494.1168

Exact Mass Matches: 494.1168

Found 65 metabolites which its exact mass value is equals to given mass value 494.1168, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Salvianolic acid A

(2R)-3-(3,4-dihydroxyphenyl)-2-[(E)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid

C26H22O10 (494.1213)

Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation. Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.

5-Methoxyhydnocarpin

5-Methoxyhydnocarpin-D

C26H22O10 (494.1213)

11a-Hydroxy-7-chlortetracycline

C22H23ClN2O9 (494.1092)

Phenolphthalein glucuronide

3,4,5-trihydroxy-6-{4-[1-(4-hydroxyphenyl)-3-oxo-1,3-dihydro-2-benzofuran-1-yl]phenoxy}oxane-2-carboxylic acid

C26H22O10 (494.1213)

Salvianolic acid A

3-(3,4-dihydroxyphenyl)-2-[(3-{2-[2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl}prop-2-enoyl)oxy]propanoic acid

C26H22O10 (494.1213)

Salvianolic

BENZENEPROPANOIC ACID, .ALPHA.-(((2E)-3-(2-((1E)-2-(3,4-DIHYDROXYPHENYL)ETHENYL)-3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPENYL)OXY)-3,4-DIHYDROXY-, (.ALPHA.R)-

C26H22O10 (494.1213)

Salvianolic acid A is a stilbenoid. Salvianolic acid A is under investigation in clinical trial NCT03908242 (Phase I Study of Continuous Administration of Salvianolic Acid A Tablet). Salvianolic acid A is a natural product found in Salvia miltiorrhiza, Salvia flava, and other organisms with data available. D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors D000970 - Antineoplastic Agents Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation. Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.

12,13-dihydro-3,4,5,7-tetrahydroxy-12-hydroxymethyl-13-(17-hydroxyl-16,18-dimethoxyphenyl)-7H-benzo[c]xanthen-4-one|falloconvolin B

C26H22O10 (494.1213)

3,4,5,6,8,13-Hexahydro-2-methyl-8,13-dioxo-2,6-epoxy-2H-anthra[2,3-b]oxocin-7,9,11-triyl=triacetate

C26H22O10 (494.1213)

5-O-beta-D-glucopyranosyl-6-[(1E,3E)-6-hydroxy-1,3-hexadienyl]-2-hydroxymethyl-thieno[2,3-e]isobenzofuran-8(6H)-one|echinothiophene

C23H26O10S (494.1247)

FLUORESCEIN MONO-BETA-D-GALACTOPYRANOSIDE

C26H22O10 (494.1213)

Phenolphthalein β-D-glucuronide

C26H22O10 (494.1213)

DICHLOROBIS[2-(DI-I-PROPYLPHOSPHINO)ETHYLAMINE]RUTHENIUM (II), MIN

C16H40Cl2N2P2Ru (494.1087)

2,5-Bis[4-(acryloyloxy)benzoyl]isosorbide

C26H22O10 (494.1213)

1-[5-methyl-2-(trifluoromethyl)furan-3-yl]-3-[(2Z)-5-(2-{[6-(1H-1,2,4-triazol-3-ylamino)pyrimidin-4-yl]amino}ethyl)-1,3-thiazol-2(3H)-ylidene]urea

C18H17F3N10O2S (494.1209)

96574-01-5

Benzenepropanoic acid, alpha-((3-(2-(2-(3,4-dihydroxyphenyl)ethenyl)-3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-3,4-dihydroxy-, (R-(E,E))-

C26H22O10 (494.1213)

D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors D000970 - Antineoplastic Agents Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation. Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.

indol-3-ylmethylisothiocyanate-glutathione

C20H24N5O6S2- (494.1168)

Salvianolicacid A

C26H22O10 (494.1213)

5-methoxyhydnocarpin-D

C26H22O10 (494.1213)

A flavonolignan isoalted from Mimosa diplotricha.

4-(4-Acetyloxyphenyl)benzoic acid [2-[[2-(2-chloroanilino)-2-oxoethyl]-methylamino]-2-oxoethyl] ester

C26H23ClN2O6 (494.1245)

4-chloro-N-[(2R,3S,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2S,3R,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2S,3S,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2S,3R,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2S,3S,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2R,3R,6R)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2R,3S,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

4-chloro-N-[(2R,3R,6S)-6-[2-[4-(3-fluorophenyl)-1-triazolyl]ethyl]-2-(hydroxymethyl)-3-oxanyl]benzenesulfonamide

C22H24ClFN4O4S (494.1191)

11a-Hydroxychlorotetracycline

C22H23ClN2O9 (494.1092)

[(1S)-2-[2-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-2-carboxyethyl]selanyl-1H-imidazol-5-yl]-1-carboxyethyl]-trimethylazanium

C17H28N5O7Se+ (494.1154)

ALDH1A1-IN-2

C25H23ClN4O3S (494.1179)

ALDH1A1-IN-2 is a potent inhibitor of aldehyde dehydrogenase 1a1 (aldh1a1). Aldehyde dehydrogenases (ALDH) constitute a family of enzymes that play a critical role in oxidizing various cytotoxic xenogenic and biogenic aldehydes. ALDH1A1-IN-2 has the potential for the research of cancer, inflammation, or obesity (extracted from patent WO2019089626A1, compound 295)[1].